Compare AU

Compare CURE vs. QMAX

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Nasdaq 100 Yield Max (Managed Fund) (QMAX). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

QMAX

Popularity

Low

Low

Pearlers invested

80

7

Median incremental investment

$620.00

$1,582.66

Median investment frequency

Monthly

Monthly

Median total investment

$1,318.91

$7,444.85

Average age group

> 35

> 35


Key Summary

CURE

QMAX

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

QMAX.AX was created on 2022-10-04 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. QMAX.AX aims to provide regular income along with exposure to a portfolio of the top 100 companies listed on the Nasdaq stock market.

Top 3 holdings

Neurocrine Biosciences Inc (2.78 %)

AbbVie Inc (2.58 %)

Alnylam Pharmaceuticals Inc (2.56 %)

NDX UL 02/21/25 C22225 (0 %)

INVESCO NASDAQ 100 ETF (59.15 %)

BETASHARES NASDAQ 100 ETF (39.60 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Other (99.97 %)

Communication Services (0.00 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (97.16 %)

Netherlands (0.95 %)

Brazil (0.69 %)

Management fee

0.45 %

0.68 %


Key Summary

CURE

QMAX

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.68 %

Price

$49.09

$31.23

Size

$36.111 million

$29.409 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

3.00 %

Market

ASX

ASX

First listed date

12/11/2018

06/10/2022

Purchase fee

$6.50

$6.50


Community Stats

CURE

QMAX

Popularity

Low

Low

Pearlers invested

80

7

Median incremental investment

$620.00

$1,582.66

Median investment frequency

Monthly

Monthly

Median total investment

$1,318.91

$7,444.85

Average age group

> 35

> 35


Pros and Cons

CURE

QMAX

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

QMAX

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home